TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

Men with PAH had a larger right heart size and worse survival than women, independent of body size and functional status, a ...

Columnist Anna Jeter appreciates how much her maternal grandparents meant to her family as she dealt with pulmonary hypertension.

Tectonic Therapeutic (TECX) stock surges on positive interim data from Phase 1b trial for lead candidate TX45 in patients ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading ... Researchers Identify Over 2,000 Genetic Signals Linked to Blood ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary ...

CF Pharmtech Guangzhou Ltd. and CF Pharmtech Hongkong Ltd. have identified prodrugs of treprostinil reported to be useful for the treatment of pulmonary hypertension and pulmonary fibrosis.